Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
Thursday, September 14, 2023 1 min read
Key Takeaway: Xenon Pharmaceuticals Inc. announced its participation in TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit scheduled for September 20, 2023. The company will be represented by Ian Mortimer, President and CEO, and Sherry Aulin, CFO, during a live webcast presentation. This event highlights Xenon's commitment to developing innovative therapies for neurological disorders, particularly in neurology and epilepsy. The webcast will be accessible via the company's website, allowing for broader audience engagement.
Market Sentiment Analysis
POSITIVE FACTORS
Xenon Pharmaceuticals is presenting at a respected industry summit.
The company focuses on innovative therapeutics for neurological disorders.
The presentation features key executives, enhancing investor engagement.
Full Press Release Details
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit to be held on September 20, 2023.
Company Fireside Chat Presentation Details:
Date:
Wednesday, September 20, 2023
Time:
4:20 pm Eastern Time
Webcast:
Register here
Presenters:
Ian Mortimer, President and Chief Executive Officer Sherry Aulin, Chief Financial Officer
A live webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.